By utilizing human stem-cell derived cardiomyocyte assays and organoids, researchers can effectively assess the proarrhythmic potential of new drugs without using animal models. The IntraCell solution allows for easy observation of beating cells in vitro and can help labs meet their 3 R’s goals (Replacement, Reduction, Refinement) as well as adhere to CiPA (Comprehensive In Vitro Proarrhythmia Assay) initiative standards.